The progression of regional atrophy in premanifest and early Huntington's disease: A longitudinal voxel-based morphometry study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 7, 2010, Pages 756-763

  Hobbs, Nicola Z ^a   Henley, Susie M D ^a   Ridgway, Gerard R ^a   Wild, Edward J ^a   Barker, Roger A ^b   Scahill, Rachael I ^a   Barnes, Josephine ^a   Fox, Nick C ^a,c   Tabrizi, Sarah J ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN STEM; CAPSULA INTERNA; CONTROLLED STUDY; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MORPHOMETRICS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PRIORITY JOURNAL; SCORING SYSTEM; THALAMUS; WHITE MATTER; ATROPHY; BRAIN; COHORT ANALYSIS; DISEASE COURSE; FEMALE; GENETICS; IMAGE PROCESSING; MALE; MIDDLE AGED; MOVEMENT (PHYSIOLOGY); NUCLEOTIDE REPEAT; PATHOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; SAMPLE SIZE; STATISTICAL MODEL;

ADULT; ATROPHY; BRAIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; IMAGE PROCESSING, COMPUTER-ASSISTED; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, STATISTICAL; MOVEMENT; REGRESSION ANALYSIS; REPETITIVE SEQUENCES, NUCLEIC ACID; SAMPLE SIZE;

EID: 77954666250     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.190702     Document Type: Article

References (44)

1. Halliday GM, McRitchie DA, Macdonald V, et al. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol 1998;154:663-72. (Pubitemid 29044235)
2. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008;131:1057-68.
3. Ruocco HH, Lopes-Cendes I, Li LM, et al. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Braz J Med Biol Res 2006;39:1129-36. (Pubitemid 44241274)
4. Ciarmiello A, Cannella M, Lastoria S, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006;47:215-22. (Pubitemid 46780885)
5. Rosas HD, Tuch DS, Hevelone ND, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 2006;21:1317-25.
6. Kipps CM, Duggins AJ, Mahant N, et al. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 2005;76:650-5. (Pubitemid 40569674)
7. Henley SM, Wild EJ, Hobbs NZ, et al. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord 2009;24:932-6.
8. Ruocco HH, Bonilha L, Li LM, et al. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry 2008;79:130-5. (Pubitemid 351236541)
9. Scahill RI, Schott JM, Stevens JM, et al. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 2002;99:4703-7.
10. Whitwell JL, Anderson VM, Scahill RI, et al. Longitudinal patterns of regional change on volumetric MRI in frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2004;17:307-10.
11. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Huntington Study Group. Mov Disord 1996;11:136-42.
12. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3. (Pubitemid 9051179)
13. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998;17:87-97.
14. Clarkson MJ, Ourselin S, Nielsen C, et al. Comparison of phantom and registration scaling corrections using the ADNI cohort. Neuroimage 2009;47:1506-13.
15. Whitwell JL, Crum WR, Watt HC, et al. Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. Am J Neuroradiol 2001;22:1483-9.
16. Lewis EB, Fox NC. Correction of differential intensity inhomogeneity in longitudinal MR images. Neuroimage 2004;23:75-83. (Pubitemid 39119437)
17. Freeborough PA, Fox NC. Modeling brain deformations in Alzheimer's disease by fluid registration of serial 3D MR images. J Comput Assist Tomogr 1998;22:838-43.
18. Barnes J, Lewis EB, Scahill RI, et al. Automated measurement of hippocampal atrophy using fluid-registered serial MRI in AD and controls. J Comput Assist Tomogr 2007;31:581-7. (Pubitemid 47457674)
19. Ashburner J, Friston KJ. Voxel - based morphometrydthe methods. Neuroimage 2000;11:805-21.
20. Ashburner J. Computational anatomy with the SPM software. Magn Reson Imaging 2009;27:1163-74.
21. Ridgway GR, Omar R, Ourselin S, et al. Issues with threshold masking in voxelbased morphometry of atrophied brains. Neuroimage 2009;44:99-111.
22. Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 1997;53:15-25.
23. Kloppel S, Stonnington CM, Chu C, et al. Automatic classification of MR scans in Alzheimer's disease. Brain 2008;131:681-9. (Pubitemid 351294712)
24. Kloppel S, Chu C, Tan GC, et al. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology 2009;72:426-31.
25. Chang CC, Lin CJ. LIBSVM: a library for support vector machines. 2001. Software available at http://www.csie.ntu.edu.tw/~cjlin/libsvm.
26. Wilson SM, Ogar JM, Laluz V, et al. Automated MRI-based classification of primary progressive aphasia variants. Neuroimage 2009;47:1558-67.
27. Vemuri P, Gunter JL, Senjem ML, et al. Alzheimer's disease diagnosis in individual subjects using structuralMRimages: validation studies. Neuroimage 2008;39:1186-97.
28. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002;15:870-8. (Pubitemid 34852500)
29. Penney JB Jr, Vonsattel JP, MacDonald ME, et al. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-92.
30. Fox NC, Cousens S, Scahill R, et al. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2000;57:339-44. (Pubitemid 30140520)
31. Langbehn DR, Brinkman RR, Falush D, et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-77. (Pubitemid 38443548)
32. Fennema-Notestine C, Archibald SL, Jacobson MW, et al. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 2004;63:989-95.
33. de la Monte SM, Vonsattel JP, Richardson EP Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988;47:516-25.
34. Kloppel S, Draganski B, Golding CV, et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008;131:196-204.
35. Brandt J, Shpritz B, Codori AM, et al. Neuropsychological manifestations of the genetic mutation for Huntington's disease in presymptomatic individuals. J Int Neuropsychol Soc 2002;8:918-24. (Pubitemid 35355860)
36. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15:552-60. (Pubitemid 30333230)
37. Rosas HD, Koroshetz WJ, Chen YI, et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003;60:1615-20.
38. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57:369-84.
39. Specht K, Minnerop M, Muller-Hubenthal J, et al. Voxel-based analysis of multiplesystem atrophy of cerebellar type: complementary results by combining voxel-based morphometry and voxel-based relaxometry. Neuroimage 2005;25:287-93. (Pubitemid 40289156)
40. Aylward EH, Rosenblatt A, Field K, et al. Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. Brain Res Bull 2003;62:137-41. (Pubitemid 37443659)
41. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63:883-90. (Pubitemid 43882298)
42. Rosenblatt A, Liang KY, Zhou H, et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006;66:1016-20. (Pubitemid 44044784)
43. Shelbourne PF, Keller-McGandy C, Bi WL, et al. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum Mol Genet 2007;16:1133-42. (Pubitemid 47062710)
44. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.